[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1958

Clinical and Laboratory Features of Malignant Carcinoid

Author Affiliations

Bethesda, Md.

Section of Experimental Therapeutics, National Heart Institute.

AMA Arch Intern Med. 1958;102(6):936-938. doi:10.1001/archinte.1958.00260230082011
Abstract

It is only a few years since Thorson1 and others recognized the association of several unusual signs and symptoms with carcinoid tumors of the small bowel with hepatic metastases. It is apparent now that (1) carcinoid (argentaffinoma) is an endocrine tumor which produces the pharmacologically active agent, serotonin (5-hydroxytryptamine), and (2) the various manifestations of the "carcinoid syndrome" are attributable to secretion of serotonin by the tumors and a disturbance in the metabolism of tryptophan.2 Since many cases of the disorder have now been recognized,3,4 both the general practitioner and the specialist should be aware of this condition and become acquainted with the simple chemical test 5 on urine by which it may be diagnosed.

Clinical Features  A series of baffling illnesses extending over a period of years is typical, coinciding with slow growth of the tumor. Current clinical concepts are derived chiefly from study of advanced

First Page Preview View Large
First page PDF preview
First page PDF preview
×